Researchers looked at three families with a history of colon cancer who doctors thought might have Lynch syndrome, a genetic condition that increases cancer risk. They used genetic testing to search for changes in the MSH2 gene, which is often involved in Lynch syndrome. The study found a different genetic variant in each family. In two families, the variants were confirmed to be disease-causing. In the third family, the variant's effect was unclear and labeled as 'uncertain significance.' The researchers also found one brand new genetic change that had not been seen before, which they classified as disease-causing. This was a very small study of only three families, which means the findings cannot be applied to most people. It was an observational case series, which is an early form of research that describes findings but doesn't prove cause and effect. The study did not report any safety concerns from the genetic testing itself. The main reason to be careful is that this research doesn't tell us anything about whether finding these variants changes a person's actual cancer risk or health outcomes. It also doesn't provide guidance on what to do if a variant of uncertain significance is found. Readers should understand this as a preliminary genetic analysis that helps scientists understand the variety of changes that can occur in the MSH2 gene. It provides evidence for the importance of precise genetic screening and counseling, but it is not yet practice-changing for patients.
Case series identifies MSH2 variants in three families suspected of Lynch syndromeGenetic study identifies Lynch syndrome variants in three families with colon cancer history
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This research article describes a case series investigating three families with suspected Lynch syndrome. The study used genetic screening via whole-exome sequencing and immunohistochemical analysis to characterize pathogenic variants in the MSH2 gene, with no comparator group reported. The population consisted of three families, though the clinical setting was not specified.
In Family 1, researchers identified the missense variant NM_000251.3:c.2633A>T:p.E878V, which was classified as a variant of uncertain significance. Family 2 had the missense variant NM_000251.3:c.998G>A:p.C333Y, confirmed as pathogenic. Family 3 showed a novel frameshift deletion, NM_000251.3:c.507del:p.Q170Rfs*4, identified as a pathogenic variant. No effect sizes, absolute numbers, p-values, or confidence intervals were reported for these findings.
Safety and tolerability data were not reported. The study has several important limitations: it included only three families, providing a very small sample size; it was an observational case series design without statistical testing; and it reported no clinical outcome data for affected individuals. The authors note this provides experimental evidence for precision screening and genetic counseling, but causation was not established.
For clinical practice, these findings should be interpreted with caution. The identification of specific MSH2 variants, including one novel pathogenic variant, in suspected Lynch syndrome families adds to the genetic characterization of this condition. However, the extremely limited sample size and lack of clinical correlation mean these results are preliminary. Clinicians should await confirmation from larger, more robust studies before applying these specific genetic findings to counseling or management decisions.
More on Lynch Syndrome
View Original Abstract ↓
Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis
Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients
Related in Rheumatology
From Other Specialties
